Eikon Therapeutics

Biotech & Life Sciences · Hayward, United States · Founded 2019 · IPO 2026

Pioneering a new method of drug discovery based on tracking and measuring movement of individual proteins in live cells

Valuation $242M

Power Law Unicorn$1–10B valuation tier

Talent graph

Eikon Therapeutics's talent

Book a demo to see the people

Employees mapped 435 incl. 9 AI specialists

Founders /100 quality score

Key operators 11 quality /100

Potential founders likely future founders

Startup mafia alumni-founded startups

Talent movements in · out past 12 months

Source: Dealroom Talent Intelligence.

Investors

24 investors on Eikon Therapeutics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Seed 1 investor entered at this stage

Lux Capital

Series A 3 investors entered at this stage

Innovation Endeavors

The Column Group

Foresite Capital

Series B+ 20 investors entered at this stage

Harel Group

The Howard Hughes Medical Institute

General Catalyst

CPP Investments

Soros Fund Management

Alexandria Venture Investments

E15 VC

Horizons Ventures

UC Investments

Abu Dhabi Investment Authority

Hartford HealthCare Endowment

EcoR1 Capital

Janelia

AME Cloud Ventures

StepStone Group

Soros Capital Management

Schroders

T. Rowe Price

University of California

Berkeley

Ownership

Who owns Eikon Therapeutics

Share of equity by holder, from Dealroom's shareholder data. Stakes as last recorded by Dealroom (May/2026).

34.6% Founders

See the full cap table on Dealroom →

Global footprint

Where Eikon Therapeutics has talent and traffic

Workforce by country

4 countries with
team presence

🇺🇸 United States99.3%

🇩🇰 Denmark0.3%

🇭🇰 Hong Kong0.3%

🇨🇦 Canada0.3%

4 countries shown

Web traffic by country

12K monthly visits
across markets

🇺🇸 United States85%

🇮🇳 India13.3%

🇯🇵 Japan3.3%

🇩🇪 Germany0.8%

Top 4 markets shown

Patent intelligence

$36M patent portfolio · 58 active families

Estimated portfolio value

$36M

14.7% of market cap · 1.5× larger than top peer Recursion Pharma ($23M)

58 active patent families

Where Eikon Therapeutics innovates AlgorithmBioinformaticsBiophysicsCellCell biology

Where Eikon Therapeutics concentrates vs peers

Each axis is a top-10 topic across Eikon Therapeutics and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Eikon Therapeutics

An AI-synthesized read of the highest-engagement posts about Eikon Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Eikon Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles